Christoph W.G. Engeler

  • Partner
  • Warburgstrasse 50
  • 20354 Hamburg
  • Germany
  • T +49.40.4140.3360


Christoph Engeler is a partner in the Hamburg office. Mr. Engeler practices in the firm’s Corporate Department, focusing on corporate and regulatory matters in the healthcare and life sciences industries.

He has a wealth of experience advising domestic and international hospital and nursing home operators as well as financial investors in healthcare institutions on M&A transactions and restructurings. He further advises public authorities on privatizations of healthcare institutions and joint ventures.

In the life sciences sector, Mr. Engeler advises German and foreign pharmaceuticals companies and manufacturers of medical devices on M&A transactions as well as German and EU regulatory matters, including clinical trials, manufacturing, marketing authorizations, distribution, promotion and marketing, interaction with healthcare professionals, vigilance, and reimbursement.

Mr. Engeler is regularly recommended by leading publications (JUVE, Chambers, The Legal 500, Handelsblatt Best Lawyers). Christoph Engeler is "very quick at grasping industry-specific concepts covered in negotiations, understanding what the client is trying to achieve and conveying it to the counterparty." (Chambers Europe Germany 2017). “Life Science Star for Germany in particular for Financial & Transactional” (LMG Life Sciences 2015).


Mr. Engeler’s experience includes advising: 

  • Antin Infrastructure Partners on the acquisition of laboratory group amedes 
  • Astellas Pharma on the acquisition of Ganymed Pharmaceuticals, and sale of its dermatology business to LEO Pharma 
  • Capvis Equity Partners on the acquisition of a majority stake in Amann Girrbach, an Austria-based manufacturer of laboratory equipment for dental technicians and dental laboratories 
  • Chequers Capital on the sale of Deutsche Fachpflege group (DFG) 
  • Juno Therapeutics on its cross-border acquisition of Stage Cell Therapeutics GmbH, a privately held biotechnology company
  • Novo A/S on the strategic investment in Evotec AG, a CRO providing drug discovery services
  • Rhön-Klinikum AG, e.g., on intended take-over by DAX listed Fresenius SE as well as on the €3.07 billion sale of 43 Hospitals to Fresenius
  • Ongoing advice to SHL Telemedizin GmbH including on transactions such as the acquisition of Almeda GmbH and Gesellschaft für Patientenhilfe
  • Siemens in connection with legal separation of the global healthcare division (diagnostic medical devices) − one of the largest in this industry − involving more than 200 countries as well as the subsequent IPO of Siemens Healthineers.
  • The Carlyle Group regarding the acquisition and subsequent sale of Alloheim, one of the largest nursing home operators
  • University Hospital Eppendorf, Hamburg regarding the structuring of the hospital’s proposed transition to foundation ownership and regarding various projects, including outsourcing and change of legal formation as well as international hospital cooperations

Thought Leadership

  • Time to Prepare for New EU Medical Device Regime -  May 24, 2019
  • MHRA Releases No-Deal Brexit Guidance for Life Sciences Companies -  April 04, 2019
  • How A No-Deal Brexit Would Affect Life Sciences Cos. -  January 16, 2019
  • Kooperationen von Krankenhäusern – Rechtliche Entwicklungen und Erfahrungsbericht -  September 2010
Bar Qualification
  • New York
  • Rechtsanwalt (Germany)
  • LLM, University of Chicago Law School, 2000
  • Second German State Exam, Higher Regional Court, Hamburg, 1999
  • First German State Exam, University of Hamburg, 1996
  • Healthcare & Life Sciences
  • German
  • English
  • European Union Life Sciences Regulatory
  • Life Science Licensing
  • Mergers & Acquisitions